Form 4: Cytokinetics Executive Sells Shares
Insider Transaction (Form 4)
Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 10,000 shares of common stock on August 31, 2026 for $70.24 per share.
Summary
- Option exercise/conversion: acquired 10,000 Common Stock at $23.26 ($232,600) on August 31, 2026; holds 68,555 after (Direct).
- Open-market sale: disposed of 10,000 Common Stock at $70.24 ($702,400) on August 31, 2026; holds 58,555 after (Direct).
- Option exercise/conversion: disposed of 10,000 Non-Qualified Stock Option (Right to Buy) on August 31, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $702,400 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Andrew Callos — Officer (EVP, Chief Commercial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-31 | Option exercise/conversion | Common Stock | 10,000 | $23 | $232.6K | 68,555 |
| 2026-08-31 | Open-market sale | Common Stock | 10,000 | $70 | $702.4K | 58,555 |
| 2026-08-31 | Option exercise/conversion | Non-Qualified Stock Option (Right to Buy) | 10,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-31 | Option exercise/conversion (10,000 shares) |
| 2026-08-31 | Open-market sale (10,000 shares) |
| 2026-08-31 | Option exercise/conversion (10,000 shares) |
Keywords
insider transaction, Form 4, CYTK, CYTOKINETICS INC, bearish, Andrew Callos
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.